1. A 61-year-old man with alcoholic cirrhosis (Child-Pugh class C, bilirubin 6.2 mg/dL, albumin 2.1 g/dL, INR 2.4) is admitted with fever, abdominal pain, and CT findings of complicated diverticulitis with localized perforation. His creatinine is 0.8 mg/dL and estimated creatinine clearance is 88 mL/min. IV metronidazole is ordered as part of empiric coverage. The clinical pharmacist flags the order for review. Which of the following most accurately describes the appropriate pharmacokinetic adjustment and the basis for it?
A) No adjustment is required because metronidazole is eliminated entirely by renal excretion, and this patient's creatinine clearance of 88 mL/min confirms normal renal function and complete drug clearance; Child-Pugh scoring is irrelevant to metronidazole dosing.
B) Dose reduction is warranted because metronidazole undergoes primary hepatic elimination through oxidation and glucuronidase conjugation; severe hepatic impairment (Child-Pugh class C) prolongs its half-life beyond the normal 6 to 10 hours due to reduced hepatic metabolic capacity, increasing the risk of neurotoxic accumulation; no reduction is needed for his normal renal function since parent drug clearance is hepatic, not renal.
C) The dose must be reduced by 50 percent for renal impairment because metronidazole and its active hydroxy-metabolite both undergo renal tubular secretion, and even minor reductions in creatinine clearance below 90 mL/min are sufficient to cause clinically significant drug accumulation requiring dose adjustment.
D) The order should be cancelled and metronidazole replaced with clindamycin, which is the preferred anaerobic agent in hepatic failure because it undergoes renal rather than hepatic elimination and does not require dose adjustment in cirrhosis; metronidazole is absolutely contraindicated in Child-Pugh class C disease.
E) No pharmacokinetic adjustment is needed for either hepatic or renal impairment because metronidazole distributes primarily into the intravascular compartment with a volume of distribution below 0.1 L/kg; cirrhosis-related hypoalbuminemia increases free drug but simultaneously reduces the volume of distribution, offsetting the reduction in hepatic clearance and maintaining stable plasma concentrations.
ANSWER: B
Rationale:
Metronidazole is eliminated predominantly by hepatic metabolism — primarily through oxidative side-chain hydroxylation and glucuronide conjugation — and its systemic clearance depends critically on hepatic metabolic capacity. Under normal conditions, the half-life is approximately 6 to 10 hours, supporting twice-daily or three-times-daily dosing. In severe hepatic impairment such as Child-Pugh class C cirrhosis, reduced hepatic blood flow, decreased hepatocyte mass, and impaired enzyme activity combine to substantially reduce metronidazole clearance and prolong the half-life, increasing the risk of drug and metabolite accumulation. Neurological adverse effects — peripheral neuropathy, encephalopathy, cerebellar toxicity — are dose- and exposure-dependent, making accumulation clinically consequential in a patient who may already have hepatic encephalopathy. A dose reduction (typically to once or twice daily, or a 50 percent reduction in total daily dose) is therefore indicated. Critically, this patient's normal renal function (CrCl 88 mL/min) is not the relevant variable: metronidazole parent drug is cleared hepatically, and only inactive metabolites appear in urine; renal impairment alone does not require metronidazole dose adjustment.
Option A: Option A is incorrect because metronidazole is not eliminated by renal excretion of the parent drug; the primary elimination route is hepatic metabolism, and Child-Pugh class directly governs the need for dose adjustment.
Option C: Option C is incorrect because a creatinine clearance of 88 mL/min does not require metronidazole dose reduction; renal tubular secretion is not a clinically significant elimination pathway for the active parent drug, and the threshold for renal-related concern does not exist for metronidazole in the way described.
Option D: Option D is incorrect because metronidazole is not absolutely contraindicated in Child-Pugh class C disease; dose reduction is warranted but the drug remains usable; clindamycin is eliminated by hepatic CYP3A4 metabolism and also requires dose reduction in severe hepatic impairment, and it cannot serve as a CNS-penetrating anaerobic substitute.
Option E: Option E is incorrect because metronidazole has a volume of distribution of approximately 0.6 to 1.0 L/kg — not below 0.1 L/kg — reflecting broad tissue distribution; hypoalbuminemia does increase the free drug fraction but does not offset reduced clearance through a volume-of-distribution reduction in the mechanistic way described.
2. A 44-year-old man completes a seven-day course of oral metronidazole 500 mg twice daily for bacterial vaginosis in his partner — he was treated simultaneously for a co-infection. He takes his last dose on a Friday evening. On Saturday afternoon he attends a family celebration and has three glasses of wine, developing flushing, severe nausea, vomiting, palpitations, and headache within 30 minutes. He calls the clinic. Which of the following most accurately explains what happened and what he should be told about alcohol avoidance going forward?
A) The patient is experiencing a type I IgE-mediated anaphylactic reaction to a metronidazole-alcohol adduct formed in the gastrointestinal tract; because this is an immune-mediated reaction, he is at risk for anaphylaxis with any future metronidazole exposure and must carry an epinephrine auto-injector; alcohol avoidance is no longer relevant since his course is complete.
B) The patient is experiencing acute metronidazole toxicity caused by alcohol-induced inhibition of CYP2E1, the enzyme responsible for metronidazole elimination; alcohol competition at CYP2E1 doubled the metronidazole half-life, resulting in drug accumulation to toxic plasma levels; he should avoid alcohol for two weeks until all metronidazole and its metabolites are eliminated.
C) The patient is experiencing the disulfiram-like reaction to metronidazole; because he has already taken his last dose, no further reaction is possible; alcohol restriction was only necessary during active therapy, and since the course is complete he may resume normal alcohol consumption immediately.
D) The patient experienced a vasovagal episode triggered by the emotional stress of the family celebration, coincidentally occurring after alcohol consumption; metronidazole has no pharmacological interaction with ethanol because the disulfiram-like reaction only occurs with IV metronidazole formulations that contain propylene glycol, not with oral tablets.
E) The patient is experiencing the disulfiram-like reaction caused by metronidazole's inhibition of aldehyde dehydrogenase, producing acetaldehyde accumulation; although his last dose was the previous evening, metronidazole and its active metabolites persist in the body, and he must avoid all alcohol-containing beverages, foods, and medications for at least 48 hours after the last dose to prevent recurrence.
ANSWER: E
Rationale:
Metronidazole produces a disulfiram-like reaction by inhibiting aldehyde dehydrogenase (ALDH), the mitochondrial enzyme that oxidizes acetaldehyde to acetate during ethanol metabolism. Acetaldehyde accumulation causes vasodilatation, flushing, palpitations, nausea, vomiting, and headache — collectively the disulfiram-like syndrome. This patient took his last dose approximately 18 to 20 hours before consuming alcohol. The critical pharmacological point is that metronidazole and its active metabolites persist in the body after the last dose, continuing to inhibit ALDH. The half-life of metronidazole is approximately 6 to 10 hours, meaning that 18 hours after the last dose, appreciable drug remains. Current guidelines and prescribing information recommend avoiding alcohol for at least 48 hours after completing a metronidazole course. This patient's reaction demonstrates the clinical reality of that recommendation: completing the course does not mean immediate ALDH recovery. He should be advised to avoid all alcohol — including alcohol-containing foods, mouthwash, and medications — for a full 48 hours after his final tablet.
Option A: Option A is incorrect because the disulfiram-like reaction is a pharmacological (non-immune) interaction, not an IgE-mediated anaphylactic reaction; it does not predict anaphylaxis with future metronidazole exposure and does not require epinephrine prescription; alcohol avoidance remains relevant for 48 hours after the last dose.
Option B: Option B is incorrect because the mechanism is inhibition of aldehyde dehydrogenase — downstream of ethanol metabolism — not CYP2E1 competition; alcohol does not double metronidazole's half-life through CYP2E1 inhibition; the two-week avoidance period described is excessive and not the established recommendation.
Option C: Option C is incorrect because alcohol avoidance must continue for at least 48 hours after the last dose; the drug and its metabolites persist and the ALDH inhibition is not immediately reversed; resuming alcohol consumption immediately after completing the course risks exactly the reaction this patient experienced.
Option D: Option D is incorrect because the disulfiram-like reaction occurs with oral metronidazole tablets, not exclusively with IV formulations; propylene glycol in IV formulations is a separate toxicity concern; this patient's reaction is pharmacologically explained by ALDH inhibition from the oral drug.
3. A 55-year-old woman with Crohn's disease has been on metronidazole 500 mg three times daily for six weeks for a perianal fistula. She now reports progressively worsening numbness and burning in both feet, worse at night, with tingling extending to the ankles. Neurological examination shows reduced vibration sense and absent ankle reflexes bilaterally. She denies any alcohol use, her vitamin B12 is normal, and her hemoglobin A1c is 5.3 percent. Which of the following is the most appropriate next step in management?
A) Discontinue metronidazole immediately — the clinical picture is consistent with metronidazole-induced peripheral neuropathy caused by mitochondrial toxicity in distal peripheral neurons; while partial recovery may occur after stopping the drug, continued exposure risks permanent axonal injury, and the drug must be stopped regardless of whether the fistula has responded to therapy.
B) Continue metronidazole at the current dose and add oral gabapentin for symptomatic neuropathy management; metronidazole-induced peripheral neuropathy is a reversible side effect that resolves while the drug is continued as long as adequate symptom control is maintained with adjuvant analgesics.
C) Reduce the metronidazole dose to 250 mg twice daily — dose reduction to below the neurotoxicity threshold will arrest progression of neuropathy while maintaining therapeutic drug concentrations for the fistula; full-dose discontinuation is only necessary if symptoms progress to involve the hands.
D) Obtain nerve conduction studies before making any medication changes — metronidazole-induced neuropathy cannot be diagnosed clinically and must be confirmed electrophysiologically before the drug is stopped, because stopping metronidazole prematurely in a patient with active Crohn's disease may precipitate disease flare requiring systemic corticosteroids.
E) Switch the patient from oral to topical metronidazole gel applied directly to the perianal fistula; topical administration eliminates systemic drug absorption and therefore eliminates the neuropathy risk while maintaining local antibacterial efficacy; the established neuropathy will fully resolve within two weeks of switching to topical therapy.
ANSWER: A
Rationale:
This patient presents with a classic picture of metronidazole-induced peripheral neuropathy: length-dependent sensory symptoms (feet first, ascending), developing after six weeks of continuous therapy at a standard dose, in a patient with no other explanation (normal B12, non-diabetic hemoglobin A1c, no alcohol use). The mechanism is mitochondrial toxicity in peripheral neurons — metronidazole and its metabolites impair mitochondrial oxidative phosphorylation in the metabolically demanding distal axons, producing dying-back axonopathy. The appropriate management is immediate drug discontinuation. Continued exposure with ongoing mitochondrial toxicity risks permanent axonal injury that does not recover after the drug is stopped. Partial recovery of neuropathy symptoms occurs in many patients after discontinuation, but this is not guaranteed, and the degree of recovery correlates with the extent of axonal damage at the time of stopping. Waiting for symptoms to progress to the hands, dose-reducing rather than stopping, or adding symptomatic medication while continuing exposure all represent inappropriate management that accepts ongoing nerve injury.
Option B: Option B is incorrect because adding symptomatic treatment and continuing the drug is not acceptable management for an established toxic neuropathy; gabapentin treats symptoms without addressing the cause, and continued metronidazole exposure risks permanent axonal damage.
Option C: Option C is incorrect because dose reduction is not a validated strategy for managing established metronidazole neuropathy; there is no established safe lower threshold for continued therapy once neuropathy has manifested, and stopping the drug is the appropriate action.
Option D: Option D is incorrect because nerve conduction studies are not required before discontinuing a drug in a patient with a clinically clear toxic neuropathy presentation; waiting for electrophysiological confirmation delays necessary drug discontinuation and risks further axonal injury; the diagnosis is clinically established by the temporal relationship, the drug's known toxicity, and the absence of other explanations.
Option E: Option E is incorrect because topical metronidazole gel does not achieve adequate concentrations in perianal fistula tissue to treat a deep tissue infection; perianal fistulas require systemic antibiotic therapy; topical application is not a recognized treatment modality for this indication.
4. A 19-year-old otherwise healthy man presents with a 4 cm fluctuant abscess on his right forearm. Incision and drainage is performed and wound cultures return positive for methicillin-resistant Staphylococcus aureus (MRSA). The susceptibility report reads: oxacillin — resistant; erythromycin — resistant; clindamycin — susceptible; TMP-SMX — susceptible. The intern writes for oral clindamycin 300 mg three times daily for seven days. Before the prescription is sent, a clinical pharmacist calls to discuss the susceptibility report. Which of the following best describes the action the pharmacist is most likely recommending and the reason for it?
A) The pharmacist is recommending switching to oral TMP-SMX because TMP-SMX is listed as susceptible and clindamycin resistance is always present when erythromycin is resistant in MRSA; there is no circumstance in which clindamycin can be safely used in an MRSA isolate that is erythromycin-resistant.
B) The pharmacist is recommending adding erythromycin to the clindamycin regimen because erythromycin-resistance combined with clindamycin-susceptibility indicates a synergistic killing phenotype in which the combination achieves bactericidal activity superior to either agent alone; monotherapy with clindamycin in this phenotype carries a high probability of treatment failure.
C) The pharmacist is recommending that a D-zone test be performed before prescribing clindamycin because the pattern of erythromycin-resistant, clindamycin-susceptible MRSA may represent inducible MLSB resistance — the erm gene is present but not constitutively expressed, and clindamycin can induce its expression in vivo, leading to treatment failure; if the D-zone test is positive (D-shaped inhibition zone), clindamycin should not be used and TMP-SMX would be an appropriate alternative.
D) The pharmacist is recommending extending the clindamycin course to 14 days because community-acquired MRSA abscesses in the erythromycin-resistant phenotype require a longer course to prevent inducible resistance from developing during therapy; seven days is insufficient to eradicate the organism before resistance emerges.
E) The pharmacist is recommending oral vancomycin instead of clindamycin because oral vancomycin is the only agent with demonstrated bactericidal activity against community-acquired MRSA skin infections; clindamycin is bacteriostatic and is therefore inferior to oral vancomycin for any MRSA infection requiring eradication rather than growth inhibition.
ANSWER: C
Rationale:
The pharmacist has correctly identified a critical susceptibility report pattern that requires additional testing before clindamycin can be safely prescribed. The combination of erythromycin-resistant and clindamycin-susceptible in an MRSA isolate is the specific phenotype that triggers concern for inducible MLSB resistance. The erm gene (erythromycin ribosome methylation gene) encodes a 23S rRNA methyltransferase that confers high-level resistance to macrolides, lincosamides, and streptogramin B. When the erm gene is expressed constitutively, the isolate is resistant to both erythromycin and clindamycin. When expressed inducibly, however, the gene is suppressed under routine testing conditions, making the isolate appear clindamycin-susceptible on standard disk diffusion — but erythromycin-resistant because erythromycin is a strong inducer. During clindamycin therapy in vivo, clindamycin itself (a weak inducer) can derepress the erm gene, leading to high-level clindamycin resistance and clinical treatment failure. The D-zone test detects this by placing erythromycin and clindamycin disks close together on the agar plate: erythromycin induces erm expression in organisms near the clindamycin disk, producing a flattened D-shaped zone of inhibition rather than a circular one. A positive D-zone test means clindamycin is unsafe; TMP-SMX, to which the organism is susceptible, is an appropriate oral alternative for this uncomplicated skin and soft tissue infection.
Option A: Option A is incorrect because it is not true that clindamycin can never be safely used when erythromycin is resistant; the critical distinction is between inducible resistance (D-zone positive — clindamycin unsafe) and true susceptibility (D-zone negative — clindamycin safe to use); the D-zone test exists precisely to make this distinction.
Option B: Option B is incorrect because adding erythromycin to clindamycin is not a recognized treatment strategy for inducible MLSB MRSA; combination therapy does not achieve synergistic bactericidal activity in this phenotype, and erythromycin would act as an inducer of erm expression, worsening the resistance problem.
Option D: Option D is incorrect because extending the clindamycin course to 14 days does not prevent emergence of inducible resistance; duration does not address the molecular resistance mechanism, and prescribing clindamycin without D-zone testing risks treatment failure from day one of therapy.
Option E: Option E is incorrect because oral vancomycin is not absorbed from the gastrointestinal tract and achieves negligible systemic concentrations; it is used exclusively for intraluminal GI infections such as Clostridioides difficile; it is not an appropriate treatment for systemic MRSA skin and soft tissue infections.
5. A 72-year-old woman is on post-operative day three following a left hemicolectomy for diverticular disease. She develops fever, abdominal distension, and high-output watery stool through her nasogastric tube. Stool testing returns positive for Clostridioides difficile toxin. Abdominal radiograph shows dilated loops of bowel consistent with ileus. She is nil per os. The resident writes for IV metronidazole 500 mg every 8 hours. An infectious diseases consultant reviews the case and modifies the treatment plan. Which of the following best explains the consultant's concern and the most important addition to the regimen?
A) The consultant adds IV vancomycin because IV metronidazole does not achieve adequate serum concentrations in post-operative patients with bowel edema; IV vancomycin achieves superior plasma levels that diffuse passively into the edematous bowel wall where C. diff toxins are produced, providing better luminal antibacterial activity than metronidazole.
B) The consultant replaces IV metronidazole with IV fidaxomicin because fidaxomicin is the only agent available in IV formulation that has intraluminal activity against C. diff; metronidazole must not be used in post-operative patients because it is excreted in bile and accumulates to toxic levels in patients with post-operative cholestasis.
C) The consultant notes that this patient has severe C. diff (ileus is a severity marker) and recommends switching from IV metronidazole monotherapy to oral vancomycin alone, since oral vancomycin is always superior to IV metronidazole and ileus does not affect vancomycin delivery from the stomach through a nasogastric tube.
D) The consultant adds vancomycin 125 mg four times daily administered via the nasogastric tube, because C. diff infection must be treated with agents that achieve intraluminal colonic concentrations — oral/NG vancomycin achieves high luminal concentrations while being minimally absorbed systemically; IV metronidazole does reach the colon via biliary secretion but in the setting of ileus with suspected severe disease, NG vancomycin is added to ensure intraluminal activity; IV metronidazole may be retained as an adjunct given the ileus.
E) The consultant replaces all antibiotics with IV immunoglobulin, which is the preferred treatment for severe C. diff infection in post-operative patients because it neutralizes C. diff toxins A and B directly in the bloodstream; antibiotic therapy is avoided because further disruption of the gut microbiome worsens C. diff severity in the immediate post-operative period.
ANSWER: D
Rationale:
This case illustrates the critical pharmacological principle that C. diff infection is a luminal disease caused by organisms and toxins within the colon, and effective treatment requires drugs that achieve high intraluminal concentrations. Oral vancomycin is poorly absorbed from the gastrointestinal tract, which is a pharmacokinetic advantage for C. diff treatment — the drug passes through the small bowel and reaches the colon at very high concentrations that kill C. diff without significant systemic absorption. In a patient with ileus who is nil per os, oral vancomycin can be administered via nasogastric tube to achieve these intraluminal concentrations. IV vancomycin, by contrast, achieves excellent systemic concentrations but does not reach the colonic lumen at therapeutic concentrations because it has no route to active intestinal secretion. IV metronidazole does reach the colon via biliary secretion and to some extent via intestinal secretion, but its colonic concentrations with ileus are uncertain and current guidelines no longer support metronidazole as first-line for any severity of C. diff. In the setting of ileus (a severity marker), NG vancomycin is the key addition. Some guidelines also support adding IV metronidazole to NG vancomycin in complicated/severe ileus-associated C. diff as an adjunct given the uncertainty about whether NG vancomycin moves adequately through a paralyzed bowel, though rectal vancomycin enemas may also be considered.
Option A: Option A is incorrect because IV vancomycin does not achieve therapeutic intraluminal colon concentrations and is not an appropriate treatment for C. diff; C. diff lives in the colon, not in the bloodstream or bowel wall, and systemic vancomycin concentrations have no direct effect on luminal C. diff.
Option B: Option B is incorrect because fidaxomicin is not available in IV formulation; it is an oral-only agent; and metronidazole is not contraindicated in post-operative patients on the basis of cholestatic bile accumulation in the manner described.
Option C: Option C is incorrect because oral vancomycin alone via nasogastric tube is reasonable, but the premise that ileus does not affect nasogastric vancomycin delivery misses the concern — ileus may impair transit through the small bowel and into the colon, which is why some guidelines support combination therapy or rectal vancomycin in complicated ileus-associated C. diff.
Option E: Option E is incorrect because IV immunoglobulin is not the preferred treatment for severe C. diff and is not a guideline-recommended first-line intervention; antibiotic therapy targeting intraluminal C. diff is the standard of care.
6. A 71-year-old woman with stage 4 chronic kidney disease (CKD; creatinine clearance [CrCl] 22 mL/min), hypertension, and type 2 diabetes presents with two days of dysuria and urinary frequency. She is afebrile with no flank pain. Urinalysis confirms pyuria and bacteriuria. She has no drug allergies. Urine culture is pending. The resident considers nitrofurantoin. Which of the following best identifies why nitrofurantoin is contraindicated in this patient and selects the most appropriate oral alternative?
A) Nitrofurantoin is contraindicated because CKD stage 4 impairs renal glucuronidase activation of the drug, preventing it from reaching its active form in the urine; the appropriate alternative is oral TMP-SMX, which is the preferred first-line agent for uncomplicated cystitis in all patients with CKD because renal impairment increases tubular concentrations of both trimethoprim and sulfamethoxazole to levels that enhance antibacterial potency.
B) Nitrofurantoin is contraindicated because CrCl below 30 mL/min produces inadequate urinary drug concentrations (eliminating efficacy) while causing systemic accumulation that increases the risk of peripheral neuropathy and pulmonary toxicity; an appropriate alternative is fosfomycin 3 g as a single oral dose, which achieves very high urinary concentrations via renal excretion and is safe in CKD.
C) Nitrofurantoin is contraindicated solely because of its nephrotoxic potential in CKD, as the drug accumulates in renal proximal tubular cells and accelerates progression to end-stage renal disease; the appropriate alternative is oral amoxicillin-clavulanate, which is the preferred empiric agent for uncomplicated cystitis in patients with CKD because it is eliminated by both hepatic and renal routes, reducing tubular drug concentrations.
D) Nitrofurantoin is contraindicated because it requires active tubular secretion for urinary excretion, and CKD stage 4 causes near-complete loss of proximal tubular secretory capacity; since the drug cannot reach the urine, no antibacterial activity is possible; the appropriate alternative is IV ceftriaxone because oral antibiotics cannot achieve adequate urinary concentrations in patients with CrCl below 30 mL/min.
E) Nitrofurantoin is contraindicated in this patient not because of renal impairment but because her type 2 diabetes creates an anaerobic urinary environment that prevents nitroreductase-mediated drug activation; diabetic patients universally require aerobic-metabolism-independent antibiotics such as TMP-SMX or ciprofloxacin for UTI treatment because nitrofurantoin is inactive in their urine.
ANSWER: B
Rationale:
Nitrofurantoin's contraindication at CrCl below 30 mL/min is based on two simultaneous pharmacological failures. First, inadequate urinary concentrations: nitrofurantoin requires active renal excretion to reach the high urine concentrations necessary for antibacterial efficacy; at CrCl 22 mL/min, the rate of drug delivery to the urine is insufficient to achieve therapeutic concentrations in the bladder lumen. Second, systemic accumulation: drug and metabolites that would normally be excreted rapidly into urine instead accumulate in the circulation, increasing exposure to peripheral neuropathy (mitochondrial neurotoxicity) and pulmonary toxicity (acute hypersensitivity pneumonitis or chronic interstitial fibrosis). Fosfomycin 3 g as a single oral dose is a pharmacologically appropriate alternative: it achieves urinary concentrations several hundred times the MIC for susceptible E. coli via renal excretion; its mechanism (irreversible MurA inhibition) is completely distinct from beta-lactams, sulfonamides, and nitrofurans; and importantly, it is usable in CKD because the single-dose regimen limits systemic exposure even in patients with impaired clearance, and the urinary concentration achieved after a single dose remains adequate in most patients with moderate-to-severe CKD — though in severe CKD the dose may require adjustment in some formulation-specific guidance.
Option A: Option A is incorrect because nitrofurantoin is not a prodrug requiring renal glucuronidase activation; the macrocrystalline formulation refers to crystal size affecting GI absorption, not enzymatic activation in the kidney; TMP-SMX is not preferred in CKD because trimethoprim inhibits renal tubular creatinine and potassium secretion, risking hyperkalemia and pseudocreatininemia in a patient already on CKD management.
Option C: Option C is incorrect because nephrotoxic acceleration of CKD progression is not the established pharmacological basis for the nitrofurantoin CKD contraindication; the recognized reasons are inadequate urinary concentration and peripheral/pulmonary toxicity; amoxicillin-clavulanate is not the preferred first-line empiric agent for uncomplicated cystitis, and its selection is not based on dual-route elimination reducing tubular concentrations.
Option D: Option D is incorrect because nitrofurantoin reaches urine through both glomerular filtration and tubular secretion, but the claim of near-complete loss of proximal tubular secretory capacity making no urine drug achievable is an overstatement; the practical issue is that total urinary drug delivery falls below therapeutic levels at CrCl below 30 mL/min; IV ceftriaxone is not necessary for uncomplicated lower UTI and is not indicated in this clinical scenario.
Option E: Option E is incorrect because diabetes mellitus does not create an anaerobic urinary environment; urine from diabetic patients is oxygenated and does not impair nitroreductase activation in uropathogens; nitrofurantoin activity depends on bacterial nitroreductase in the organisms, not on urine oxygen tension.
7. A 41-year-old man with HIV and a CD4 count of 38 cells/mm³ is admitted with progressive dyspnea and bilateral interstitial infiltrates. Bronchoscopy confirms Pneumocystis jirovecii pneumonia (PCP) and he is started on high-dose TMP-SMX (15 mg/kg/day of the trimethoprim component). On day five, routine labs show: serum potassium 6.4 mEq/L (baseline 4.1 mEq/L), serum creatinine 1.4 mg/dL (baseline 0.9 mg/dL). He has no cardiac symptoms and his ECG shows peaked T waves. He is not receiving any other medications known to cause hyperkalemia. Which of the following best explains the mechanism of his hyperkalemia and guides the most appropriate management?
A) The hyperkalemia is caused by sulfamethoxazole-induced adrenal insufficiency; SMX inhibits cortisol and aldosterone synthesis by blocking the CYP11B1 and CYP11B2 enzymes in the adrenal cortex, reducing mineralocorticoid-driven urinary potassium secretion; hydrocortisone replacement is required, and TMP-SMX must be discontinued due to the absolute contraindication of sulfonamide use in adrenal insufficiency.
B) The hyperkalemia and creatinine rise both represent trimethoprim-induced acute tubular necrosis; TMP is directly toxic to proximal tubular cells at high doses, causing tubular dysfunction that impairs potassium secretion and reduces creatinine clearance; TMP-SMX should be discontinued and replaced with pentamidine, which has no renal tubular toxicity.
C) The hyperkalemia is caused by TMP-SMX-induced rhabdomyolysis; sulfonamides at high doses cause oxidative injury to skeletal muscle cells in HIV-positive patients, releasing intracellular potassium; the elevated creatinine reflects both acute kidney injury from myoglobinuria and direct sulfonamide nephrotoxicity; creatine kinase should be checked and TMP-SMX discontinued.
D) The hyperkalemia results from TMP-SMX-induced myelosuppression causing hemolysis of red blood cells, releasing intracellular potassium; the concurrent creatinine elevation reflects acute kidney injury from hemoglobin-mediated renal tubular toxicity; the combination of hemolysis and renal injury requires immediate TMP-SMX discontinuation and packed red blood cell transfusion.
E) Trimethoprim blocks epithelial sodium channels (ENaC) in the cortical collecting duct — using a mechanism analogous to the potassium-sparing diuretic amiloride — reducing sodium reabsorption and the lumen-negative electrochemical gradient that drives potassium secretion into the tubular lumen; the creatinine rise reflects trimethoprim's competitive inhibition of tubular creatinine secretion, not true GFR reduction; management includes close electrolyte monitoring, consideration of dose reduction or potassium-lowering measures, and continuation of TMP-SMX if the clinical PCP situation requires it.
ANSWER: E
Rationale:
Trimethoprim has structural similarity to amiloride, a potassium-sparing diuretic, and acts by the same mechanism: blockade of epithelial sodium channels (ENaC) on the luminal surface of principal cells in the cortical collecting duct. Under normal physiology, ENaC-mediated sodium reabsorption creates a lumen-negative electrical potential that drives potassium secretion via ROMK (renal outer medullary potassium) channels into the tubular lumen. When trimethoprim blocks ENaC, sodium reabsorption decreases, the lumen-negative potential falls, and potassium secretion is impaired — producing potassium retention and hyperkalemia. This effect is dose-dependent and most prominent at the high doses used for PCP treatment (as opposed to prophylaxis). The creatinine elevation of 1.4 from a baseline of 0.9 mg/dL represents trimethoprim's separate action: competitive inhibition of organic cation and anion transporters in the proximal tubule that are responsible for tubular creatinine secretion, raising serum creatinine without reducing true GFR. Management of the hyperkalemia requires assessment of severity (peaked T waves warrant urgent attention), electrolyte supplementation or correction if needed, and a clinical decision about whether TMP-SMX can be continued for the PCP at a modified dose or whether a switch to an alternative (pentamidine, atovaquone) is necessary. Abrupt TMP-SMX discontinuation for PCP should be avoided if possible, as it is the most effective agent.
Option A: Option A is incorrect because TMP-SMX does not inhibit adrenal CYP11B1 or CYP11B2; ketoconazole and metyrapone inhibit adrenal steroidogenesis, not TMP-SMX; adrenal insufficiency is not a recognized adverse effect of this drug combination.
Option B: Option B is incorrect because trimethoprim does not cause acute tubular necrosis; the creatinine elevation is a pharmacological effect on tubular creatinine secretion without true GFR reduction, not tubular necrosis; pentamidine itself has significant renal toxicity and is not nephrotoxically superior to TMP-SMX.
Option C: Option C is incorrect because TMP-SMX-induced rhabdomyolysis in HIV patients is not a recognized clinical entity causing hyperkalemia; sulfonamide oxidative muscle injury as described is not an established mechanism; the hyperkalemia in this patient is explained by ENaC blockade by trimethoprim.
Option D: Option D is incorrect because TMP-SMX myelosuppression (from folate depletion) can cause hemolysis in G6PD-deficient patients, but hemolysis is not the mechanism of hyperkalemia in this patient; the concurrent creatinine elevation is explained by tubular secretion blockade, not hemoglobin nephrotoxicity; packed red blood cell transfusion is not indicated based on this presentation.
8. A 58-year-old woman with acute myeloid leukemia is on day 22 of induction chemotherapy. She has been neutropenic for 18 days and has been receiving broad-spectrum antibiotics including meropenem for the past 10 days for a fever of unknown origin. She develops new fever, productive cough, and bilateral lower lobe infiltrates. Bronchoalveolar lavage culture grows Stenotrophomonas maltophilia. Susceptibility results show resistance to meropenem, ciprofloxacin, and gentamicin; susceptibility to TMP-SMX and ticarcillin-clavulanate. The team asks why meropenem — which has covered most Gram-negative pathogens in this patient — is not active against this organism. Which of the following most accurately explains the intrinsic resistance mechanism and the first-line treatment choice?
A) Stenotrophomonas maltophilia is intrinsically resistant to carbapenems because it chromosomally encodes a class B metallo-beta-lactamase (L1) that hydrolyzes all carbapenem antibiotics; TMP-SMX is the established first-line treatment because Stenotrophomonas retains dependence on de novo folate synthesis and the folate pathway is fully susceptible to sequential DHPS and DHFR inhibition; the organism's resistance to fluoroquinolones and aminoglycosides reflects efflux pump expression and other intrinsic mechanisms.
B) Stenotrophomonas maltophilia is intrinsically resistant to carbapenems because it lacks the outer membrane porins required for carbapenem entry, but the resistance is reversible — meropenem administered at double the standard dose achieves intracellular concentrations sufficient to kill the organism; TMP-SMX is not recommended because Stenotrophomonas can synthesize folate from exogenous sources, making it less susceptible to DHPS inhibition than organisms fully dependent on de novo synthesis.
C) Stenotrophomonas maltophilia carbapenem resistance is caused by the organism's obligate intracellular lifestyle, which prevents carbapenem molecules from penetrating the host cell membrane; TMP-SMX is effective because it is actively concentrated inside host cells, achieving bactericidal intracellular concentrations that carbapenems cannot reach; this is the same mechanism by which TMP-SMX treats Pneumocystis jirovecii infection.
D) Stenotrophomonas maltophilia resistance to carbapenems is caused by transferable plasmid-encoded carbapenemases acquired from Pseudomonas aeruginosa during the period of meropenem exposure; this is a hospital-acquired resistance acquisition, not intrinsic resistance; TMP-SMX must be combined with meropenem because neither agent alone is sufficient for bactericidal activity against plasmid-mediated carbapenem-resistant strains.
E) Stenotrophomonas maltophilia is intrinsically resistant to carbapenems because carbapenems are prodrugs that require hydrolysis by a renal dehydropeptidase for activation; Stenotrophomonas lacks the outer membrane transport proteins needed to uptake the activated carbapenem metabolite, while TMP-SMX requires no transport for entry because trimethoprim and sulfamethoxazole diffuse freely across all Gram-negative outer membranes.
ANSWER: A
Rationale:
Stenotrophomonas maltophilia's intrinsic carbapenem resistance is a well-characterized feature arising from chromosomally encoded beta-lactamases — specifically the class B metallo-beta-lactamase L1 (which hydrolyzes carbapenems, cephalosporins, and penicillins) and the class A serine-beta-lactamase L2 (which inactivates many cephalosporins). L1 is a metallo-beta-lactamase that uses zinc ions in its catalytic mechanism and can hydrolyze all carbapenems including meropenem, imipenem, and ertapenem. This intrinsic resistance means that prolonged meropenem exposure in this patient was not the cause of resistance emergence — the organism was always carbapenem-resistant and its recovery reflects selection of a pre-existing resistant pathogen from the patient's environment or flora during broad-spectrum antibiotic pressure. TMP-SMX is the established first-line treatment for Stenotrophomonas infections because the organism cannot import preformed folate from its environment and must synthesize it de novo through the DHPS-catalyzed pathway; both DHPS (targeted by SMX) and DHFR (targeted by TMP) are fully present and susceptible, making sequential pathway inhibition effective.
Option B: Option B is incorrect because Stenotrophomonas resistance to carbapenems is mediated by enzymatic hydrolysis (L1 metallo-beta-lactamase), not by porin absence; doubling the meropenem dose cannot overcome enzyme-mediated hydrolysis; and Stenotrophomonas cannot import preformed folate, making it dependent on de novo synthesis and therefore susceptible to TMP-SMX.
Option C: Option C is incorrect because Stenotrophomonas maltophilia is not an obligate intracellular pathogen; it is an environmental Gram-negative bacillus that causes extracellular infections; the intracellular mechanism described is relevant to organisms such as Mycobacterium or Legionella, not Stenotrophomonas.
Option D: Option D is incorrect because Stenotrophomonas carbapenem resistance is chromosomally encoded and intrinsic, not plasmid-acquired from Pseudomonas; while horizontal gene transfer of resistance genes occurs in clinical environments, the L1 metallo-beta-lactamase is a stable chromosomal feature of Stenotrophomonas maltophilia present in all clinical isolates.
Option E: Option E is incorrect because carbapenems are not prodrugs requiring renal dehydropeptidase activation for antibacterial activity; imipenem does require cilastatin co-administration to prevent renal dehydropeptidase inactivation, but meropenem is stable to dehydropeptidase and does not require this; the mechanism described is fabricated.
9. A 67-year-old man in the surgical ICU is on day five of IV colistin for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii (CRAB). His baseline creatinine was 0.9 mg/dL. Today's creatinine is 2.1 mg/dL with urine output decreasing to 0.4 mL/kg/hr over the past 12 hours. He has been euvolemic and is not receiving any other nephrotoxic agents. He remains febrile and has not yet shown clinical improvement. Which of the following best describes the most likely cause of the renal deterioration and the appropriate clinical approach?
A) The renal deterioration is caused by CRAB bacteremia superimposed on the pneumonia, producing sepsis-associated acute kidney injury; the creatinine rise is unrelated to colistin therapy; colistin should be continued at the current dose and additional coverage added for possible bloodstream infection with the same organism.
B) The creatinine rise represents colistin-induced tubular secretion blockade analogous to the trimethoprim-creatinine interaction; true GFR is preserved and urine output is decreasing because colistin reduces renal tubular potassium secretion, causing osmotic shifts that transiently reduce urine volume; no dose adjustment is needed and the elevation will resolve spontaneously.
C) The creatinine rise and reduced urine output are consistent with colistin-induced nephrotoxicity, which occurs in approximately 30 to 60 percent of patients receiving IV colistin and is the primary dose-limiting adverse effect; management requires assessment of whether the patient's CRAB isolate has any other active agents — if no alternatives exist, colistin must be dose-adjusted for the new renal function and continued with close monitoring; if an alternative is available, transitioning reduces further nephrotoxic exposure.
D) The creatinine rise represents an expected and clinically insignificant pharmacological effect of colistimethate sodium hydrolysis products that inhibit tubular creatinine secretion; true GFR is preserved; the decreasing urine output reflects colistin's direct stimulation of antidiuretic hormone (ADH) release from the posterior pituitary, causing water retention that is self-limited and resolves with fluid restriction.
E) The creatinine rise indicates that this patient has developed colistin-resistant CRAB during therapy; organisms that become resistant to colistin simultaneously develop enhanced production of biofilm that reduces glomerular filtration by obstructing renal tubules with bacterial debris; a repeat susceptibility test should be ordered and colistin should be continued at double the current dose until resistance is confirmed.
ANSWER: C
Rationale:
Colistin-induced nephrotoxicity is the primary and most clinically significant dose-limiting adverse effect of IV colistin, occurring in approximately 30 to 60 percent of patients in published clinical series. The mechanism involves direct tubular toxicity — colistin accumulates in proximal tubular cells, disrupting mitochondrial membrane potential and causing tubular cell injury that reduces tubular function and GFR. This patient's creatinine doubling from 0.9 to 2.1 mg/dL with decreasing urine output in the absence of other nephrotoxic agents and with maintained euvolemia is highly consistent with colistin-induced AKI. The clinical decision is difficult: CRAB often has no other reliable active agents. The appropriate approach is: first, confirm that no other agent is available (check susceptibility to alternatives such as sulbactam-containing combinations, minocycline, cefiderocol if available); second, if an alternative exists, transition to it to limit further nephrotoxic exposure; third, if colistin is the only active agent, dose-adjust for the current creatinine and continue with intensive renal monitoring. Discontinuing colistin without an alternative for active CRAB infection risks clinical deterioration and mortality, while unchecked nephrotoxicity risks dialysis-dependent renal failure.
Option A: Option A is incorrect because attributing the creatinine rise to CRAB bacteremia without evidence of bloodstream infection while already on colistin — which should be active against the same organism — is not the most likely explanation; colistin nephrotoxicity is a common and expected complication at this time point in therapy and should be the primary consideration.
Option B: Option B is incorrect because colistin does not produce a tubular creatinine secretion blockade analogous to trimethoprim; colistin nephrotoxicity is a true tubular toxicity causing GFR reduction, not a pharmacological interference with creatinine measurement; the ADH stimulation mechanism described is fabricated.
Option D: Option D is incorrect because colistimethate sodium hydrolysis products do not inhibit tubular creatinine secretion in the manner described; the creatinine elevation from colistin nephrotoxicity reflects true GFR reduction, and colistin does not stimulate ADH release as a mechanism of decreased urine output.
Option E: Option E is incorrect because colistin resistance does not manifest as biofilm-induced tubular obstruction reducing GFR; resistance in CRAB typically involves modification of lipid A phosphate groups reducing colistin binding, not biofilm production causing renal injury; attributing the creatinine rise to a fabricated resistance mechanism while recommending dose doubling is pharmacologically unsound.
10. A 52-year-old woman with a mechanical mitral valve prosthesis is maintained on warfarin with a target INR of 2.5 to 3.5. Her current INR is 3.0, checked two weeks ago. She presents with vaginal discharge and is diagnosed with Trichomonas vaginalis infection confirmed by NAAT (nucleic acid amplification test). The recommended treatment is metronidazole 2 g as a single oral dose. Which of the following best describes the most important management consideration beyond the trichomoniasis treatment itself?
A) The single 2 g dose of metronidazole is too high for a patient with a mechanical valve because the disulfiram-like reaction to alcohol can trigger a hypertensive crisis that increases the risk of valve leaflet thrombosis; alcohol should be absolutely avoided for two weeks and the dose should be split into 500 mg four times daily over 24 hours to reduce peak metronidazole plasma concentrations and minimize aldehyde dehydrogenase inhibition.
B) Metronidazole is contraindicated in patients with mechanical heart valve prostheses because its CYP2C9 inhibition increases warfarin levels, creating a risk of hemopericardium from pericardial anti-coagulation; tinidazole, a related nitroimidazole that does not inhibit CYP2C9, should be used for trichomoniasis in all anticoagulated patients with mechanical valves.
C) The INR should be checked immediately before initiating metronidazole and the warfarin dose increased by 25 percent prophylactically to compensate for metronidazole's induction of warfarin metabolism via CYP2E1; without prophylactic dose increase, INR will fall below therapeutic range during the metronidazole course, creating thromboembolism risk for the mechanical valve.
D) Metronidazole inhibits CYP2C9, which metabolizes the pharmacologically active S-enantiomer of warfarin; this interaction potentiates warfarin and can elevate the INR significantly, which is particularly dangerous in a patient with a mechanical valve where both supratherapeutic anticoagulation (bleeding risk) and subtherapeutic anticoagulation (valve thrombosis) are life-threatening; INR should be checked within one week of the metronidazole dose and warfarin dose reduction should be anticipated.
E) No INR monitoring is required because a single 2 g dose of metronidazole has a half-life of only 30 minutes and is fully eliminated within six hours; the duration of CYP2C9 inhibition is proportional to the duration of drug exposure, and a single-dose regimen provides insufficient drug exposure to produce a clinically measurable warfarin interaction.
ANSWER: D
Rationale:
Metronidazole is a clinically important inhibitor of CYP2C9, the cytochrome P450 isoform responsible for metabolizing the pharmacologically active S-enantiomer of warfarin. The S-enantiomer is three to five times more potent as a vitamin K epoxide reductase inhibitor than the R-enantiomer, so inhibition of its clearance produces clinically significant warfarin potentiation and INR elevation. This interaction is well-documented even with single-dose metronidazole regimens, because the drug's half-life of approximately 6 to 10 hours means that meaningful CYP2C9 inhibition persists for at least 24 to 48 hours after a single 2 g dose. In a patient with a mechanical heart valve, the stakes of anticoagulation mismanagement are extremely high: supratherapeutic INR (from warfarin potentiation) risks serious bleeding including intracranial hemorrhage, while subtherapeutic INR risks prosthetic valve thrombosis with potentially fatal consequences. Close INR monitoring — ideally within five to seven days of the metronidazole dose — is mandatory, and reduction of the warfarin dose in anticipation of the interaction is frequently appropriate. The prescribing clinician must inform the patient of bleeding signs and ensure rapid access to INR testing.
Option A: Option A is incorrect because the 2 g single dose is the standard and appropriate dose for trichomoniasis treatment; splitting it does not mitigate the CYP2C9 interaction; and the mechanism described — disulfiram-like reaction causing hypertensive crisis and valve thrombosis — misrepresents the ALDH interaction and is not the primary concern; the CYP2C9 warfarin interaction is the critical management issue.
Option B: Option B is incorrect because metronidazole is not contraindicated in patients with mechanical valves; the interaction requires management, not avoidance of the drug; tinidazole is not established as free of CYP2C9 inhibition to the degree claimed, and recommending it universally instead of metronidazole for this indication is not standard practice.
Option C: Option C is incorrect because metronidazole inhibits CYP2C9, not CYP2E1; and its effect on warfarin metabolism is inhibition (raising INR), not induction (lowering INR); prophylactically increasing the warfarin dose would compound the interaction and risk dangerous supratherapeutic anticoagulation.
Option E: Option E is incorrect because metronidazole's half-life is approximately 6 to 10 hours — not 30 minutes — and the CYP2C9 inhibition from a single 2 g dose does produce clinically measurable warfarin interaction; single-dose regimens of metronidazole have been documented to elevate INR in patients on warfarin, and assuming no monitoring is needed based on a fabricated 30-minute half-life is dangerous clinical reasoning.
11. A 34-year-old woman presents to the emergency department with two days of dysuria, urinary frequency, and — since this morning — fever to 38.8°C, rigors, and right flank pain with costovertebral angle tenderness. Urinalysis shows pyuria, bacteriuria, and nitrite positivity. She was seen at an urgent care clinic yesterday and was prescribed nitrofurantoin macrocrystals 100 mg twice daily. She has taken three doses. Despite the antibiotic, her symptoms have worsened and she is now systemically ill. Renal function is normal. Which of the following best explains the treatment failure and identifies the correct management?
A) Nitrofurantoin treatment failure in this patient is caused by an emerging nitrofurantoin-resistant E. coli strain that developed resistance rapidly during the three doses taken; resistant organisms are now invading the renal parenchyma; the appropriate management is to add a second oral antibiotic with a different mechanism rather than switching agents, because organisms resistant to nitrofurantoin retain susceptibility to combination therapy.
B) Nitrofurantoin cannot treat pyelonephritis because it does not achieve therapeutic concentrations in renal parenchymal tissue or in the bloodstream; regardless of urinary drug concentrations, the renal interstitial infection and potential bacteremia cannot be eradicated by a drug confined to the urinary lumen; this patient requires systemic antibiotic therapy — such as a fluoroquinolone (if susceptibility is confirmed and not contraindicated), a third-generation cephalosporin, or IV ceftriaxone given her systemic illness — and hospitalization should be considered given the severity of presentation.
C) Nitrofurantoin failure in this patient reflects the inoculum effect — the high bacterial burden in the upper urinary tract exceeds the pharmacodynamic breakpoint achievable with oral nitrofurantoin; doubling the dose to 200 mg twice daily will achieve urinary concentrations sufficient to overcome the inoculum effect and treat the upper tract infection without requiring a change of drug class.
D) The clinical failure is explained by nitrofurantoin's activity being limited to Gram-positive organisms; this patient most likely has a Gram-negative E. coli UTI that ascended to the kidney; nitrofurantoin has no activity against any Gram-negative pathogen, and the appropriate management is immediate switch to TMP-SMX, which covers all Gram-negative uropathogens including E. coli and Klebsiella.
E) Nitrofurantoin failure is caused by the drug's inability to penetrate biofilm on the uroepithelial surface of the renal pelvis; biofilm-protected organisms in the upper urinary tract are inherently resistant to all oral antibiotics; parenteral agents are required because IV antibiotics penetrate biofilm via the renal vasculature through a mechanism unavailable to orally administered drugs.
ANSWER: B
Rationale:
This patient's clinical deterioration — progression from lower urinary tract symptoms to fever, rigors, and costovertebral angle tenderness — represents ascending infection with pyelonephritis. The prescribing clinician at the urgent care clinic made an error by selecting nitrofurantoin for what appeared to be uncomplicated cystitis without recognizing the potential for upper tract involvement, or alternatively by not reassessing the choice when systemic features developed. The fundamental pharmacokinetic limitation of nitrofurantoin is absolute: the drug is rapidly absorbed, rapidly metabolized, and excreted into urine in high concentrations, but systemic plasma concentrations and renal parenchymal tissue concentrations are sub-therapeutic. Pyelonephritis requires an antibiotic that achieves therapeutic concentrations in the renal interstitium and bloodstream, because the organisms are invading tissue and potentially entering the circulation. Continuing or increasing nitrofurantoin cannot treat a tissue infection regardless of urinary drug levels. Management requires switching to a systemic antibiotic: oral fluoroquinolones (ciprofloxacin, levofloxacin) are appropriate if susceptibility is confirmed and the patient can be managed outpatient; oral third-generation cephalosporins (cefpodoxime, cefdinir) are alternatives; IV ceftriaxone is appropriate for patients who are more severely ill or cannot tolerate oral medication. This patient's fever, rigors, and systemic appearance warrant consideration of hospitalization and IV therapy.
Option A: Option A is incorrect because nitrofurantoin resistance did not develop in three doses; resistance emergence during short antibiotic courses is not how bacterial resistance is acquired; the failure is pharmacokinetic (inadequate tissue concentrations), not microbiological (resistance emergence); and adding a second oral antibiotic while continuing nitrofurantoin does not address the tissue penetration deficiency.
Option C: Option C is incorrect because doubling the nitrofurantoin dose does not produce therapeutic renal parenchymal or systemic concentrations; nitrofurantoin pharmacokinetics do not allow dose escalation to achieve tissue penetration — the drug is intrinsically confined to urinary concentrations regardless of dose.
Option D: Option D is incorrect because nitrofurantoin does have activity against E. coli; the claim that it has no activity against any Gram-negative pathogen is inaccurate; TMP-SMX has high resistance rates in many geographic areas making it unsuitable as an automatic substitute, and its limitation for pyelonephritis involves resistance prevalence rather than the pharmacokinetic tissue-penetration issue relevant to nitrofurantoin.
Option E: Option E is incorrect because biofilm penetration is not the explanation for nitrofurantoin's failure in pyelonephritis; the mechanism is inadequate systemic and tissue concentrations; and the claim that IV antibiotics penetrate biofilm via the renal vasculature through a mechanism unavailable to oral drugs is pharmacologically inaccurate.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.